



Axxelent
Pharma Science Private Limited



Date:18.10.2024

Axxelent Receives Health Canada cGMP Compliance Certification

Axxelent Pharma Science Private Limited ("Axxelent") is pleased to announce receipt of Health Canada cGMP for its Non-Sterile facility situated in Sri City SEZ, AP. Health Canada inspected the facility from 16th -20th September 2024.

Commenting on the outcome of the inspection, Jitesh Devendra, Co-Founder and Chairman, said "We are pleased to announce successful outcome of our first Health Canada cGMP inspection for our Non-Sterile facility which covers Oral Solids, Oral Liquids and Semi-Solids. This follows completion of our first US FDA inspection in August 2024 for our Oral Solid facility. Further inspections for our other dosage forms are expected in the upcoming 12 months from other Regulatory agencies. Our next step is to trigger our Sterile facility with the qualification expected to complete by Q3 FY25. The successful completion of the regulatory inspections reflects our commitment to maintaining high standards and ensuring compliance with all regulations."

About Axxelent

Axxelent Pharma Science Private Limited ("Axxelent") headquartered in Chennai is a speciality Pharma company offering various development and manufacturing capabilities in immediate and modified release oral dosage forms, oral liquids, semi-solids, injectables and ophthalmic.

Axxelent B2B business model is focused on CDMO, Partnership and Licensing for Regulated Markets like US, Canada, Europe, UK and Australia.

Axxelent Sri City manufacturing facility comprises of two manufacturing blocks.

Block 1 – Non-Sterile Facility with Oral Solid, Oral Liquids and Semi-solids dosage forms
Block 2 - Sterile Facility for injectables and ophthalmic is currently under qualification.

Axxelent R&D is based out of IITM Research Park, Chennai. Axxelent R&D is recognised under DSIR and EoU certified.

For more information, please contact Mr. Devesh Jain at devesh@axxelent.com.